Cuorips Inc.
4894・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. Comprised of 6 directors (2 outside) and 3 corporate auditors (all outside). A Risk Management Committee has been established as an advisory body to the Board of Directors, and internal control and compliance systems have been put in place.
Risk Management
The Company has established a Risk Management Committee, chaired by the Representative Director and Executive Vice President (composed of full-time directors, full-time statutory auditors, and legal counsel), which deliberates on the identification, evaluation, and response measures for risks. The committee met once during the fiscal year under review. A three-way audit system involving the Internal Audit Office, statutory auditors, and the accounting auditor has also been established.
Shareholder Returns
The company has continued to pay no dividends since its establishment. Annual dividends are zero for both FY2026 (ending March 2026) and the FY2027 (ending March 2027) forecast. For the time being, the company prioritizes retaining funds for R&D and capital expenditures, and the possibility and timing of any future dividend payment remain undetermined.
Dividend Policy
The company has not paid any dividends since its establishment. The annual dividend for FY2026 (ending March 2026) is ¥0 (year-end dividend of ¥0), and the forecast for FY2027 (ending March 2027) is also ¥0. For the time being, the policy is to prioritize retaining funds for active R&D activities and the establishment of manufacturing and quality control systems. The company states that once it secures sufficient funds in the future, it will consider returning profits to shareholders through dividends, taking into account its business results, financial position, and a comparison with the results of enhancing corporate value through investment; however, the possibility and timing of implementation remain undetermined at this time.
ESG
The company positions its contribution to a sustainable society through the treatment of severe heart failure as a core aim, and prioritizes the enhancement of human capital as a key initiative. It discloses achievements including a 100% rate of paternity leave uptake among male employees and an average of 10.1 days of paid leave taken (achieving the target of 10.0 days). No quantitative disclosures regarding climate change are provided.
Last updated: June 24, 2026